Skip to main content

Table 1 Baseline characteristics after propensity score matching

From: Adverse effect profile of trichlormethiazide: a retrospective observational study

Characteristic

TCM users (1 mg/day) with matched controls

TCM users (2 mg/day) with matched controls

 

Users (n = 99)

Controls (n = 99)

p-value

Users (n = 61)

Controls (n = 61)

p-value

Exposure days (days, mean ± SD)

57.8 ± 14.8

-

 

63.9 ± 16.4

-

 

Age (years, mean ± SD)

65.8 ± 13.5

66.4 ± 11.4

0.7476

67.5 ± 9.9

69.2 ± 11.2

0.3741

Women

54 (55%)

61 (62%)

0.3134

26 (43%)

27 (44%)

0.8551

Medical History

      

   Diabetes mellitus

54 (55%)

57 (58%)

0.6675

42 (69%)

44 (72%)

0.6914

   Cerebrovascular diseases

33 (33%)

41 (41%)

0.2399

17 (28%)

11 (18%)

0.1964

   Ischemic heart diseases

19 (19%)

21 (21%)

0.7233

12 (20%)

11 (18%)

0.8169

   Other heart disease

42 (42%)

35 (35%)

0.3075

34 (56%)

36 (59%)

0.7143

   Liver disease

22 (22%)

24 (24%)

0.7364

27 (44%)

25 (41%)

0.7143

   Kidney disease

30 (30%)

28 (28%)

0.7548

21 (34%)

17 (28%)

0.4342

   Gout

5 (5%)

5 (5%)

1

1 (2%)

1 (2%)

1

   Thyroid disorders

27 (27%)

31 (31%)

0.5322

23 (38%)

25 (41%)

0.7109

   Hyperlipidemia

59 (60%)

56 (57%)

0.6657

50 (82%)

52 (85%)

0.6248

   COPD

5 (5%)

4 (4%)

0.733

5 (8%)

3 (5%)

0.4645

   Proteinuria

30 (30%)

32 (32%)

0.7592

22 (36%)

21 (34%)

0.8497

Past drugs

      

   Chemotherapeutic drugs

1 (1%)

0 (0%)

0.3161

3 (5%)

3 (5%)

1

   Oral antihyperglycemic drugs

10 (10%)

13 (13%)

0.5058

11 (18%)

15 (25%)

0.3765

   Lipid-lowering drugs

30 (30%)

22 (22%)

0.1964

26 (43%)

23 (38%)

0.5796

   Steroids

10 (10%)

7 (7%)

0.4467

9 (15%)

5 (8%)

0.2559

   Thyroid drugs

3 (3%)

4 (4%)

0.7004

0 (0%)

0 (0%)

-

Current antihypertensive drugs

      

   ARB

70 (71%)

67 (68%)

0.6442

35 (57%)

34 (56%)

0.8551

   AECI

21 (21%)

23 (23%)

0.7324

14 (23%)

15 (25%)

0.8316

   CCB

81 (82%)

83 (84%)

0.7063

44 (72%)

45 (74%)

0.8385

   Beta-blocker

14 (14%)

11 (11%)

0.5209

15 (25%)

13 (21%)

0.6668

   Alpha+beta-blocker

6(6%)

6 (6%)

1

3 (5%)

3 (5%)

1

   Alpha-blocker

8 (8%)

14 (14%)

0.1748

9 (15%)

8 (13%)

0.7938

   Alpha-agonist

0 (0%)

0 (0%)

-

0 (0%)

0 (0%)

-

   Vasodilator

0 (0%)

1 (1%)

0.3161

0 (0%)

0 (0%)

-

  1. Data are numbers of individuals (%) unless otherwise stated. Abbreviations: TCM, trichlormethiazide; COPD, chronic obstructive pulmonary disease; ARB, angiotensin II receptor blocker; AECI, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840